Regulatory review due to success in studies, and thanks to leap in progress made by development of mRNA COVID jab

Sheba-led research team says that 6 months after boosters, 'antibody levels and cumulative vaccine efficacy do not differ between the two vaccines'

Massachusetts-based firm accuses rival and its partner of copyright infringement, filing suit in both US and German courts

Study will assess how well special shot built to be Omicron-proof protects against infection; expert says Israel helping lead way in ‘the future of the fight against the pandemic’

CEO says US biotech firm intends to submit new vaccine to regulators, will gear up to start supplying shots by August in anticipation of infection spike in the fall

Vaccine reportedly triggers increased resistance across prior variants, although it's unclear for how long; study performed on 437 people and is not yet scientifically reviewed

VP at US pharma firm says data showing shot it developed to help counter Beta variant 'really give us hope' that boosters can be adjusted for other coronavirus strains

'The public can be assured that this vaccine was approved in keeping with the FDA’s rigorous scientific standards,' says senior regulator

Drugmaker says lab tests show half-dose booster shot increased by 37 times the level of so-called neutralizing antibodies able to fight new strain of coronavirus

Stephane Bancel says there's 'no world' in which protection will prove to be the same against new strain, says he expects a 'material drop'